Drugs / RH-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00558727 | Nov 2007 → Dec 2008 | cancer, non-Hodgkin lymphoma | Spectrum Pharmaceuticals, Inc | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RH-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00558727 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusion over 3 hours” NCT00558727 ↗ |